Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Long-Term Debt Repayments (2019)

Ptc Therapeutics (PTCT) has 4 years of Long-Term Debt Repayments data on record, last reported at $5.0 million in Q3 2019.

  • For Q3 2019, Long-Term Debt Repayments changed N/A year-over-year to $5.0 million; the TTM value through Dec 2022 reached $5.0 million, changed N/A, while the annual FY2022 figure was $150.0 million, N/A changed from the prior year.
  • Long-Term Debt Repayments reached $5.0 million in Q3 2019 per PTCT's latest filing, up from $12000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $5.0 million in Q3 2019 and bottomed at $5.0 million in Q3 2019.